Research · Sep 2, 2026
Absci (ABSI): AI-Designed Antibody ABS-201 Shows 65-Day Half-Life
Absci says interim data across ABS-201's four dose cohorts show a half-life of at least 65 days, but hair-loss efficacy and revenue impact stay unconfirmed.
ABSI
Absci Corporation
NASDAQ · Healthcare · Biotechnology · US
$8.84
+0.45%